The Year Ahead, A Forward Look - Research Report on General Mills, Inc., GlaxoSmithKline plc., Pfizer Inc., The Coca-Cola

   The Year Ahead, A Forward Look - Research Report on General Mills, Inc.,
   GlaxoSmithKline plc., Pfizer Inc., The Coca-Cola Company and Dr. Pepper
                             Snapple Group, Inc.

PR Newswire

NEW YORK, February 20, 2013

NEW YORK, February 20, 2013 /PRNewswire/ --

Today, National Traders Association announced new research reports
highlighting General Mills, Inc. (NYSE:GIS), GlaxoSmithKline plc. (NYSE:GSK),
Pfizer Inc. (NYSE:PFE), the Coca-Cola Company (NYSE: KO) and Dr. Pepper
Snapple Group, Inc. (NYSE: DPS). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

General Mills, Inc. Research Report

General Mills hit its 52-week high last week at $41.92, with The Street rating
the company as a "buy," citing revenue growth, good cash flow from operations,
net income growth, among others, which outweigh its "generally high" debt
management risk. General Mills started reducing its workforce and production
costs of other products amid acquisitions and growing wholesale orders to
avoid increasing end prices and keep up with expected revenues. However,
analysts at Goldman Sachs are not optimistic with the company's new cereal
lineup this year, and won't make up the subpar numbers elsewhere. In addition,
its Yoplait yoghurt is underperforming despite the popularity of Greek yogurt.
The Full Research Report on General Mills, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/ac13_GIS]

--

GlaxoSmithKline plc. Research Report

A cure for Alzheimer's is the main focus of GlaxoSmithKline. A research team
in University Laval in Canada has discerned a way to encourage the brains
defense system to naturally combat Alzheimer's. The breakthrough in this is
that the cure itself is already available through GlaxoSmithKline's portfolio
as it is an active ingredient in the healthcare company's records for years.
Research has tested that after injecting mice that show Alzheimer's symptoms,
within months' time the mice have shown astonishing improvement in their
ability in terms of comprehension and learning. Discoveries like this will
propagate the company's record in breakthrough medicine, and its contribution
to curing the 6th probable cause of death in the United States. The Full
Research Report on GlaxoSmithKline plc. - Including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.nationaltradersassociation.org/r/entire_report/7072_GSK]

--

Pfizer Inc. Research Report

Pfizer on the other hand recently launched its subsidiary Zoetis (NYSE: ZTS)
to the NYSE and has been making the headlines for having the biggest initial
public offering since Facebook at $26. Having a 60-year animal healthcare
history with Pfizer, it is but natural that its executive team came from its
mother company. Five out of nine of its current board members currently work
at Pfizer. The response has been more than impressive as originally its
proposed price were in the $22 to $25 dollars, but the amount of interest from
investors had led it to push its IPO price to $26 and earning an initial IPO
of US$2.24 billion. Zoetis will be trading independently from Pfizer, but the
company itself will be owned by the majority of the pharmaceutical giant.
Zoetis' debut was the biggest since Facebook's IPO in the mid-2011, earning
US$16.02 billion. The Full Research Report on Pfizer Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/bd2d_PFE]

--

The Coca-Cola Company Research Report

With these developments, top soda makers have begun looking for ways in order
to remain strong in the US and other developed countries. One of the Coca-Cola
Company's strategies was to launch an anti-obesity ad campaign, but it was
duly met with much criticism. Another strategy that Coca-Cola is using is to
expand its portfolio of non-carbonated drinks. At present, Coca-Cola has a
leading position in the juices or still beverages category with Minute Maid,
Simply and PowerAde. To add to this line of products, the company has
purchased stakes in Fair Oaks Farms Brands, LLC, a company that produces
high-protein milk shakes, creating a new portfolio of healthy beverages with
high growth potential. . The Full Research Report on The Coca-Cola Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/83ff_KO]

--

Dr. Pepper Snapple Group, Inc. Research Report

Dr. Pepper Snapple Group Inc. responded with a new line of 10 calorie versions
of 7-Up, Sunkist and three other sodas after launching a 10-calorie version of
Dr. Pepper in 2012. It is the only company that continues to thrive in the US,
with 70% of its sales coming from soda, and about 90% of its revenue from the
US. Dr. Pepper hopes to redefine the image of diet soda and win back soda
drinkers who wish to reduce their calorie intakes. Diet soda already accounts
for 20 percent of Dr. Pepper's soda sales and Larry Young, CEO of Plano, the
Texas-based Dr. Snapple Group, sees that the figure could reach between 40 to
50 percent in the next few years. The Full Research Report on Dr. Pepper
Snapple Group, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/c007_DPS]

--

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1-(702)-212-4493

SOURCE National Traders Association
 
Press spacebar to pause and continue. Press esc to stop.